• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于 Ki67 指数和转移性淋巴结比率预测甲状腺髓样癌复发的分级方案。

A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.

机构信息

Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong, 510060, PR China.

State Key Laboratory of Oncology in South China, 651 Dongfeng East Road, Guangzhou, Guangdong, 510060, PR China.

出版信息

Endocrine. 2023 Jul;81(1):107-115. doi: 10.1007/s12020-023-03328-4. Epub 2023 Feb 23.

DOI:10.1007/s12020-023-03328-4
PMID:36823341
Abstract

PURPOSE

The Ki67 index and lymph node ratio (LNR) have been proposed as components of alternative pathological classification schemes, but the most appropriate classification for patients with medullary thyroid cancer (MTC) remains unknown. The aim of the present study was to examine the usefulness of a new grading system combining the Ki67 index and LNR as a predictor of prognostic and disease-free survival (DFS) in MTC.

METHODS

We conducted a retrospective study of patients with MTC who were registered at Sun Yat-sen University Cancer Center, Guangzhou, P. R. China from June 2003 to October 2021. The DFS rates were assessed using risk-adjusted Cox proportional hazard regression modeling to explore the relationship among pathological features, nutritional status and DFS. The Ki67 index (cutoff value: 5% and 10%) and LNR (cutoff value: 0.2 and 0.3) were combined to create a new grading system.

RESULTS

In total, 101 matched patients were assessed. The integrated grading system showed better separation of Kaplan Meier (KM) curves for DFS. As the grading stage progressed, there was a significant stepwise decrease in DFS, which was better than Ki67, LNR and N staging alone. According to the grading system, the high-risk group had a worse prognosis.

CONCLUSION

The proposed grading scheme demonstrated a better prognostic performance in MTC patients than the Ki67, LNR and N staging alone. However, larger scale studies are needed to further verify our findings.

摘要

目的

Ki67 指数和淋巴结比率(LNR)已被提议作为替代病理分类方案的组成部分,但用于甲状腺髓样癌(MTC)患者的最佳分类仍不清楚。本研究旨在探讨一种新的分级系统,该系统将 Ki67 指数和 LNR 相结合,作为预测 MTC 患者预后和无病生存(DFS)的指标的有效性。

方法

我们对 2003 年 6 月至 2021 年 10 月在中山大学肿瘤防治中心登记的 MTC 患者进行了回顾性研究。使用风险调整 Cox 比例风险回归模型评估 DFS 率,以探讨病理特征、营养状况与 DFS 之间的关系。Ki67 指数(临界值:5%和 10%)和 LNR(临界值:0.2 和 0.3)相结合创建了一个新的分级系统。

结果

共评估了 101 例匹配患者。综合分级系统显示 DFS 的 Kaplan-Meier(KM)曲线分离效果更好。随着分级阶段的进展,DFS 呈显著逐步下降,明显优于 Ki67、LNR 和 N 分期。根据分级系统,高危组预后较差。

结论

与 Ki67、LNR 和 N 分期相比,该拟议的分级方案在 MTC 患者中显示出更好的预后性能。然而,需要更大规模的研究来进一步验证我们的发现。

相似文献

1
A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.一种基于 Ki67 指数和转移性淋巴结比率预测甲状腺髓样癌复发的分级方案。
Endocrine. 2023 Jul;81(1):107-115. doi: 10.1007/s12020-023-03328-4. Epub 2023 Feb 23.
2
Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer.淋巴结比率作为甲状腺髓样癌复发的预后因素的价值。
PeerJ. 2023 Mar 13;11:e15025. doi: 10.7717/peerj.15025. eCollection 2023.
3
Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients With Medullary Thyroid Cancer: A Single-Center Retrospective Study.淋巴结比率作为预测甲状腺髓样癌患者持续性/复发性疾病的预测因子:一项单中心回顾性研究。
Endocr Pract. 2024 Mar;30(3):194-199. doi: 10.1016/j.eprac.2023.11.009. Epub 2023 Nov 25.
4
Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.转移性腋窝淋巴结比率(LNR)在乳腺癌患者的预后评估方面优于pN分期——来自单一机构的804例中国患者的研究结果。
Asian Pac J Cancer Prev. 2013;14(9):5219-23. doi: 10.7314/apjcp.2013.14.9.5219.
5
The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.淋巴结比率在甲状腺髓样癌中的预后价值:一项多中心研究。
Eur J Surg Oncol. 2020 Nov;46(11):2023-2028. doi: 10.1016/j.ejso.2020.04.016. Epub 2020 Apr 18.
6
Development of a simplified tumor-lymph node ratio classification system for patients with resected gastric cancer: A western study.为接受胃癌切除术的患者开发简化的肿瘤-淋巴结比率分类系统:一项西方研究。
Ann Diagn Pathol. 2021 Feb;50:151677. doi: 10.1016/j.anndiagpath.2020.151677. Epub 2020 Dec 7.
7
Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer: A Single Center Cohort Study.替代淋巴结分类系统对甲状腺髓样癌患者预后的预测性能:一项单中心队列研究。
Ann Surg Oncol. 2022 Apr;29(4):2561-2569. doi: 10.1245/s10434-021-11134-3. Epub 2021 Dec 10.
8
Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.颈侧区淋巴结转移的儿童甲状腺癌中预测复发风险的淋巴结比值和转移淋巴结大小的最佳值。
J Pediatr Surg. 2023 Mar;58(3):568-573. doi: 10.1016/j.jpedsurg.2022.07.010. Epub 2022 Jul 13.
9
Predictive Value of the Number of Harvested Lymph Nodes and Cut-Off for Lymph Node Ratio in the Prognosis of Stage II and III Colorectal Cancer Patients.II期和III期结直肠癌患者预后中淋巴结收获数量及淋巴结比率临界值的预测价值
J Invest Surg. 2019 Jan;32(1):1-7. doi: 10.1080/08941939.2017.1369605. Epub 2017 Oct 3.
10
Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.侧颈部淋巴结比率是甲状腺乳头状癌伴淋巴结转移患者无复发生存的独立危险因素。
Endocrine. 2022 Dec;78(3):484-490. doi: 10.1007/s12020-022-03173-x. Epub 2022 Aug 26.

引用本文的文献

1
Disease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study.无病生存期和影响甲状腺髓样癌患者无病生存期的预后因素:一项多中心队列研究。
Endocrine. 2024 Sep;85(3):1300-1309. doi: 10.1007/s12020-024-03809-0. Epub 2024 Apr 3.
2
The prognostic value of lymph node ratio for thyroid cancer: a meta-analysis.甲状腺癌淋巴结比率的预后价值:一项荟萃分析。
Front Oncol. 2024 Feb 7;14:1333094. doi: 10.3389/fonc.2024.1333094. eCollection 2024.
3
Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.

本文引用的文献

1
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
2
CONUT Score: A New Tool for Predicting Prognosis in Patients with Advanced Thyroid Cancer Treated with TKI.CONUT评分:预测接受TKI治疗的晚期甲状腺癌患者预后的新工具。
Cancers (Basel). 2022 Jan 30;14(3):724. doi: 10.3390/cancers14030724.
3
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.《2021年世界卫生组织胸膜肿瘤分类:自2015年分类以来的进展》
免疫组织化学在甲状腺肿瘤的病理诊断和治疗中的应用。
Front Endocrinol (Lausanne). 2023 May 31;14:1198099. doi: 10.3389/fendo.2023.1198099. eCollection 2023.
J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10.
4
Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer: A Single Center Cohort Study.替代淋巴结分类系统对甲状腺髓样癌患者预后的预测性能:一项单中心队列研究。
Ann Surg Oncol. 2022 Apr;29(4):2561-2569. doi: 10.1245/s10434-021-11134-3. Epub 2021 Dec 10.
5
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer.用于预测甲状腺髓样癌复发的转移淋巴结比率
Cancers (Basel). 2021 Nov 21;13(22):5842. doi: 10.3390/cancers13225842.
6
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.国际甲状腺髓样癌分级系统:甲状腺髓样癌的有效分级系统。
J Clin Oncol. 2022 Jan 1;40(1):96-104. doi: 10.1200/JCO.21.01329. Epub 2021 Nov 3.
7
Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis.甲状腺乳头状癌侵袭性临床病理特征与体重指数的关系:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Jun 30;12:692879. doi: 10.3389/fendo.2021.692879. eCollection 2021.
8
Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.体重指数与甲状腺乳头状癌临床病理特征的相关性:系统评价和荟萃分析。
World J Surg. 2021 Sep;45(9):2805-2815. doi: 10.1007/s00268-021-06193-2. Epub 2021 Jun 16.
9
Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis.肥胖与癌症患者生存结局的关联:系统评价和荟萃分析。
JAMA Netw Open. 2021 Mar 1;4(3):e213520. doi: 10.1001/jamanetworkopen.2021.3520.
10
Metastatic lymph node ratio as a better prognostic tool than the TNM system in colorectal cancer.转移性淋巴结比率是比结直肠癌的 TNM 系统更好的预后工具。
Future Oncol. 2021 Apr;17(12):1519-1532. doi: 10.2217/fon-2020-0993. Epub 2021 Feb 25.